BRAF and melanoma: In 50–75% of melanomas progressing on BRAF inhibitor or combination BRAF/MEK inhibition, common resistance effectors, including BRAF copy number gains, MEK1/2 and NRAS mutations promote the reactivation of MAPK signalling2–6.